长期从事白血病的临床与基础研究，探索白血病的发病机理、靶向治疗和预后危险度分层治疗，主要研究成果：1）建立完善了白血病临床研究体系，包括方案设计、执行、质量监察、标本库、数据管理和统计，开展了一系列临床研究，探索出的治疗方案已被我国白血病治疗指南和国家卫计委的临床路径采纳。2）牵头组织制定了《中国急性髓系白血病》、《成人急性淋巴细胞白血病诊疗指南》和《慢性髓性白血病诊疗指南》三部诊治指南，对我国白血病治疗的规范化发挥了重要作用。3）应用多种技术研究白血病的发病过程，揭示了一系列的分子机制和治疗靶点。4）针对不同的靶抗原，研发了数种靶向血液肿瘤、具有自主知识产权的嵌合抗原受体T细胞(CAR-T)治疗技术，其中CD19 CAR-T等2项授权发明专利进行了技术转让；基于CD19 CAR-T技术研发的CNCT19细胞注射液，获得国家药监局药品审评中心(CDE)批准，开展成人复发或难治性急性淋巴细胞白血病 (R/R ALL)及淋巴瘤(R/R NHL)两项新药临床试验；该产品于2020年12月11日获得CDE批准，正式纳入“突破性治疗药物”，用于成人R/R ALL的治疗，有望实现先进、关键治疗技术国产化，为患者提供安全、高效和可及的免疫细胞治疗产品。
1991 中国协和医科大学医学硕士
1985 山东医学院医疗系医学学士
1999.09-至今 中国医学科学院血液病医院（中国医学科学院血液学研究所），主任医师
1994.11-1999.07 美国国立卫生研究院，访问学者
1994.04-1994.10 中国医学科学院血液病医院（中国医学科学院血液学研究所），副主任医师
1991.08-1994.03 中国医学科学院血液病医院（中国医学科学院血液学研究所），住院医师、主治医师
1990.05-1991.04 日本熊本大学医学部，访问学者
1985.08-1988.08 中国医学科学院血液病医院（中国医学科学院血液学研究所），住院医师
1. Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, Qiu S, Gu R, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Song Z, Wang Y, Li W, Mi Y, Wang J*, Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukaemia, Clin Cancer Res. 2020; 26(13):3154-3161
2. Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Yu, Jin J, Jiang H, Zhang X, Li Y, Liu L, Zhang W, Liu X, Gu J, Qiao J, Ouyang G, Liu X, Luo J, Jiang M, Xie X, Li J, Zhao C, Zhang M, Yang T, and Wang J*, Flumatinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: A Phase III, randomized, Open-label, Multi-center FESTnd Study, Clin Cancer Res. 2021;27(1):70-77
3. Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y*, Zhu X* and Wang J*, Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia, J Hematol Oncol, 2020;13(1):122
4. Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y, Xing Y, Rao Q, Xing H, Tian Z, Wang M*, Wang J*, Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model, Cytotherapy, 2020;22(10):552-562
5. Li Y, Xue Z, Dong X, Liu Q, Liu Z, Li H, Xing H, Xu Y, Tang K, Tian Z, Wang M, Rao Q*, Wang J*. Mitochondrial dysfunction and oxidative stress in bone marrow stromal cells induced by daunorubicin leads to DNA damage in hematopoietic cells, Free Radic Biol Med, 2020, 146: 211-221
6. Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M*, Wang J*, 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T-cell malignancies, J Hematol Oncol, 2019;12(1):49
7. Liu S, Xing Y, Lu W, Li S, Tian Z, Xing H, Tang K, Xu Y, Rao Q, Wang M* and Wang J*，RUNX1 inhibits proliferation and induces apoptosis of t (8;21) leukemia cells via KLF4 mediated transactivation of P57, Haematologica, 2019; 104 (8):1597-1607
8. Xu Y, Li S, Wang Y, Liu J, Mao X, Xing H, Tian Z, Tang K, Liao X, Rao Q, Xiong D, Wang M*, Wang J*, Induced CD20 expression on B-cell malignant cells heightened the cytotoxic activity of chimeric antigen receptor engineered T cells, Human Gene Therapy, 2019, 30(4): 497-510
9. Li H, Zhao N, Li Y, Xing H, Chen S, Xu Y, Tang K, Tian Z, Wang M, Rao Q*, Wang J*, c-MPL is a candidate surface marker and confers self-renewal, quiescence, chemotherapy resistance, and leukemia initiation potential in leukemia stem cells, Stem Cells, 2018;36:1685-1696
10. Wei H, Wang Y, Zhou C, Lin D, Liu B, Liu K, Qiu S, Gong B, Li Y, Zhang G, Wei S, Gong X, Liu Y, Zhao X, Gu R, Mi Y, Wang J*, Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population, J Hematol Oncol, 2018;11(1):18
11. Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, and Wang J*, CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype, Human Gene Therapy, 2018, 29(5):626-639
12. Wang Y, Xu Y, Li S, Liu J, Xing Y, Xing H, Tian Z, Tang K, Rao Q, Wang M*, and Wang J*, Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells, J Hematol Oncol. 2018; 11(1): 60
13. Chen S, Li H, Li S, Yu J, Wang M, Xing H, Tang K, Tian Z, Rao Q*, Wang J*. Rac1 GTPase promotes interaction of hematopoietic stem/progenitor cell with niche and participates in leukemia initiation and maintenance in mouse. Stem Cells. 2016; 34:1730-1741
14. Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang JM, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, and Huang X, Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina, Blood, 2015; 125(18): 2771-2778
15. Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, Xing H, Tian Z, Tang K, Mi Y, Wang B, Wang M*, and Wang J*, TBLR1 fuses to retinoid acid receptor alpha in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia, Blood, 2014, 124(6):936-945
16. Jia Y, Peng L, Rao Q, Xing H, Huai L, Yu P, Chen Y, Wang C, Wang M, Mi Y, Wang J*, Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation, FASEB J. 2014, 28: 2816-2827
17. Jin J#, Wang JX#, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ, Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial, Lancet Oncol. 2013, 14(7): 599-608
18. Wang JY, Yu P, Chen S, Xing H, Chen Y, Wang M, Tang K, Tian Z, Rao Q*, Wang J*, Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction. Mol Oncol. 2013, 7: 907-916
19. Liu J, Xing H, Chen Y, Wang L, Wang D, Rao Q, Tang K, Tian Z, He K, Wang M*, Wang J*, PIG7, transactivated by AML1, promotes apoptosis and differentiation of leukemia cells with AML1-ETO fusion gene, Leukemia, 2012, 26: 117-126
20. Zhi L, Wang M, Rao Q, Yu F, Mi Y, Wang J*, Enrichment of N-cadherin and Tie 2-bearing CD34+CD38-CD123+ leukemic stem cells by chemotherapy-resistance, Cancer Letter, 2010, 296 (1): 65-73
21. Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J*，Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia, Am J Hematol, 2009, 84: 422-427
22. Liu X, Zhang Q, Zhang DE, Zhou C, Xing H, Tian Z, Rao Q, Wang M and Wang J*, Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis, Leukemia, 2009, 23: 739-745
23. Wei H, Liu X, Xiong X, Wang Y, Rao Q, Wang M, Wang J*, AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain, FEBS Lett. 2008, 582(15): 2167-2172
24. Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, Wang M, Wang J*, Identification of a novel isoform of iASPP and its interaction with p53, J Mol Biol, 2007, 368: 1162-1171
25. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res, 1999, 59:2766-2769
26. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with human N-CoR/mSin3/HDAC1 Complex. Proc Natl Acad Sci USA, 1998, 95:10860-10865
27. Wang J, Otsuki T, Youssoufian H, Foe JL, Kim S, Devetten M, Yu J, Li Y, Dunn D, Liu JM. Overexpression of the fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res, 1998, 58(16):3538-3541
28. Wang J, Wang M, Liu JM, Transformation properties of the ETO gene, fusion partner in t(8;21) leukemias. Cancer Res, 1997, 57:2951-2955
津公网安备12010102000385号